Helene Roelofs
  • Medical Center, Leiden University, The Netherlands
Research fields
  • Stem cell
Personal information


Ph.D., Department of Molecular Genetics, Leiden University, Netherlands, 1992

Current position

Assistant professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Netherlands (since 2002)


  1. Reinders, M., Bank, J. R., Dreyer, G. J., Roelofs, H., Heidt, S., Roelen, D. L., Huurman, V., Lindeman, J., van Kooten, C., Claas, F., Fibbe, W. E., Rabelink, T. J. and de Fijter, J. W. (2014). Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients. J Transl Med 12(1): 331.
  2. Moll, G., Hult, A., von Bahr, L., Alm, J. J., Heldring, N., Hamad, O. A., Stenbeck-Funke, L., Larsson, S., Teramura, Y., Roelofs, H., Nilsson, B., Fibbe, W. E., Olsson, M. L. and Le Blanc, K. (2014). Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells? PLoS One 9(1): e85040.
  3. Roemeling-van Rhijn, M., Reinders, M. E., Franquesa, M., Engela, A. U., Korevaar, S. S., Roelofs, H., Genever, P. G., Ijzermans, J. N., Betjes, M. G., Baan, C. C., Weimar, W. and Hoogduijn, M. J. (2013). Human allogeneic bone marrow and adipose tissue derived mesenchymal stromal cells induce CD8+ cytotoxic T cell reactivity. J Stem Cell Res Ther 3(Suppl 6): 004.
  4. Roemeling-van Rhijn, M., Khairoun, M., Korevaar, S. S., Lievers, E., Leuning, D. G., Ijzermans, J. N., Betjes, M. G., Genever, P. G., van Kooten, C., de Fijter, H. J., Rabelink, T. J., Baan, C. C., Weimar, W., Roelofs, H., Hoogduijn, M. J. and Reinders, M. E. (2013). Human bone marrow- and adipose tissue-derived mesenchymal stromal cells are immunosuppressive and in a humanized allograft rejection model. J Stem Cell Res Ther Suppl 6(1): 20780.
  5. Calkoen, F. G., Jol-van der Zijde, C. M., Mearin, M. L., Schweizer, J. J., Jansen-Hoogendijk, A. M., Roelofs, H., van Halteren, A. G., Egeler, R. M., van Tol, M. J. and Ball, L. M. (2013). Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response. Biol Blood Marrow Transplant 19(11): 1590-1599.
  6. Ball, L. M., Bernardo, M. E., Roelofs, H., van Tol, M. J., Contoli, B., Zwaginga, J. J., Avanzini, M. A., Conforti, A., Bertaina, A., Giorgiani, G., Jol-van der Zijde, C. M., Zecca, M., Le Blanc, K., Frassoni, F., Egeler, R. M., Fibbe, W. E., Lankester, A. C. and Locatelli, F. (2013). Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol 163(4): 501-509.
  7. Melief, S. M., Geutskens, S. B., Fibbe, W. E. and Roelofs, H. (2013). Multipotent stromal cells skew monocytes towards an anti-inflammatory function: the link with key immunoregulatory molecules. Haematologica 98(9): e121-122.
  8. Rodrigo, S. F., van Ramshorst, J., Hoogslag, G. E., Boden, H., Velders, M. A., Cannegieter, S. C., Roelofs, H., Al Younis, I., Dibbets-Schneider, P., Fibbe, W. E., Zwaginga, J. J., Bax, J. J., Schalij, M. J., Beeres, S. L. and Atsma, D. E. (2013). Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up. J Cardiovasc Transl Res 6(5): 816-825.
  9. Melief, S. M., Schrama, E., Brugman, M. H., Tiemessen, M. M., Hoogduijn, M. J., Fibbe, W. E. and Roelofs, H. (2013). Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 31(9): 1980-1991.
  10. Reinders, M. E., Roemeling-van Rhijn, M., Khairoun, M., Lievers, E., de Vries, D. K., Schaapherder, A. F., Wong, S. W., Zwaginga, J. J., Duijs, J. M., van Zonneveld, A. J., Hoogduijn, M. J., Fibbe, W. E., de Fijter, J. W., van Kooten, C., Rabelink, T. J. and Roelofs, H. (2013). Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy. Cytotherapy 15(6): 663-672. 
  11. Melief, S. M., Geutskens, S. B., Fibbe, W. E. and Roelofs, H. (2013). Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica 98(6): 888-895.
  12. Melief, S. M., Zwaginga, J. J., Fibbe, W. E. and Roelofs, H. (2013). Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med 2012-0184.
  13. Torensma, R., Prins, H. J., Schrama, E., Verwiel, E. T., Martens, A. C., Roelofs, H. and Jansen, B. J. (2013). The impact of cell source, culture methodology, culture location, and individual donors on gene expression profiles of bone marrow-derived and adipose-derived stromal cells. Stem Cells Dev 22(7): 1086-1096.
  14. Reinders, M. E., de Fijter, J. W., Roelofs, H., Bajema, I. M., de Vries, D. K., Schaapherder, A. F., Claas, F. H., van Miert, P. P., Roelen, D. L., van Kooten, C., Fibbe, W. E. and Rabelink, T. J. (2013). Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2(2): 107-111.
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.